Strides Pharma Science Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 10,840.35 million compared to INR 9,863.7 million a year ago. Revenue was INR 10,704.89 million compared to INR 10,134.91 million a year ago. Net income was INR 181.75 million compared to net loss of INR 95.42 million a year ago. Basic earnings per share from continuing operations was INR 1.97 compared to basic loss per share from continuing operations of INR 1.06 a year ago. Diluted earnings per share from continuing operations was INR 1.97 compared to diluted loss per share from continuing operations of INR 1.06 a year ago. Basic earnings per share was INR 1.98 compared to basic loss per share of INR 1.06 a year ago. Diluted earnings per share was INR 1.97 compared to diluted loss per share of INR 1.06 a year ago.
For the full year, sales was INR 40,511.24 million compared to INR 36,883.87 million a year ago. Revenue was INR 40,908.25 million compared to INR 37,787.15 million a year ago. Net loss was INR 706.14 million compared to INR 2,026.35 million a year ago. Basic loss per share from continuing operations was INR 13.72 compared to INR 24.56 a year ago. Diluted loss per share from continuing operations was INR 13.72 compared to INR 24.56 a year ago. Basic loss per share was INR 7.76 compared to INR 22.49 a year ago. Diluted loss per share was INR 7.76 compared to INR 22.49 a year ago.